Familial Mediterranean Fever
Full Extract Cannabis Oil (FECO) is emerging as a critical therapeutic option for Familial Mediterranean Fever (FMF), especially for patients who are resistant to or cannot tolerate the standard treatment, Colchicine.
FMF is an autoinflammatory disorder caused by mutations in the MEFV gene, leading to overactive "pyrin inflammasomes."1 FECO helps manage this condition by acting as both a biological "mute button" for inflammation and a potent analgesic for the characteristic painful "attacks."
1. Mechanism: Calming the Inflammasome
FMF "attacks" are driven by an uncontrolled surge of Interleukin-1 beta (IL-1β).2 FECO addresses this systemic overreaction through several channels:
Inhibition of Pro-inflammatory Cytokines: Both CBD and THC in FECO have been shown to reduce the production of IL-1β, IL-6, and TNF-α. By lowering these "alarm signals," FECO can help reduce the overall severity and duration of a fever episode.
CRP Reduction: 2025 case studies of FMF patients homozygous for the M694V mutation showed a significant reduction in C-reactive protein (CRP) levels during attacks after starting medical cannabis treatment.
Mast Cell Stabilization: Cannabinoids help prevent mast cells from releasing histamines and other inflammatory mediators that contribute to the painful swelling of the serous membranes (lining of the abdomen, chest, and joints).
2. Benefits During an Attack
| Symptom | FECO's Benefit | Action |
|---|---|---|
| Abdominal Pain | Visceral Analgesic | Calms the sensitive nerves in the peritoneal lining, reducing the "sharp" intensity of peritonitis. |
| Joint Pain/Swelling | Anti-inflammatory | CB2 receptors in the synovium (joint lining) are activated to reduce swelling and improve mobility. |
| Pleuritic Chest Pain | Broncho-relaxation | Reduces the pain associated with deep breathing by soothing the pleural lining of the lungs. |
| High Fever | Thermoregulation | While not a primary antipyretic, FECO can help modulate the body's stress response to high temperatures, making the fever more tolerable. |
3. The "Resistant FMF" Breakthrough
A landmark report in late 2025 followed FMF patients who were "colchicine-resistant"—meaning they continued to have attacks despite the highest safe doses of standard meds.
Frequency Reduction: One patient saw their attack frequency drop from once every two weeks to once a month.
Mobility: Patients reported that even during a flare-up, they were able to remain mobile and out of bed, whereas previously they were completely incapacitated.
4. Safety and 2026 Clinical Context
The "Full Extract" Advantage: FMF involves deep, systemic pain.7 Whole-plant FECO is preferred over CBD isolates because the small amount of THC is necessary to achieve the "analgesic threshold" required for serositis pain.
Dosing (Real-World 2026): Patients often use a Day/Night split. A high-CBD/low-THC extract during the day to stay functional, and a more balanced (1:1) FECO at night to manage the severe joint and chest pain that prevents sleep.
Research Note: Because stress is a primary trigger for FMF flares, FECO’s ability to regulate the HPA axis (the body's stress system) acts as a preventative by raising the patient's threshold for "stress-induced" attacks.
